L-methylfolate in the therapeutic management of major depressive disorder

Journal of Pharmacy Practice

Volumn 21, Issue 4, 2008, Pages 278-286

  Hunter, Tracy S ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Folate therapy; L methylfolate; Major depression

Indexed keywords

ANTIDEPRESSANT AGENT; COLESTIPOL; COLESTYRAMINE; CYANOCOBALAMIN; DESIPRAMINE; FENOFIBRATE; FLUOXETINE; FOLIC ACID; FOLIC ACID DERIVATIVE; FOLINIC ACID; HOMOCYSTEINE; LAMOTRIGINE; LITHIUM; METFORMIN; METHYLENETETRAHYDROFOLIC ACID; METHYLFOLATE; MONOAMINE; NICOTINIC ACID; NITROUS OXIDE; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PROTON PUMP INHIBITOR; SALAZOSULFAPYRIDINE; SEROTONIN UPTAKE INHIBITOR;

ABSENCE OF SIDE EFFECTS; BLOOD BRAIN BARRIER; DNA METHYLATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; FOLATE METABOLISM; FOLIC ACID BLOOD LEVEL; GENETIC POLYMORPHISM; HEREDITY; HUMAN; LIFESTYLE; MAJOR DEPRESSION; MONOTHERAPY; REVIEW; RISK FACTOR; SIDE EFFECT; STANDARD; TREATMENT OUTCOME;

EID: 47649122259     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190008318132     Document Type: Review

References (69)

1. Hayden MR, Tyagi SC Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: the pleiotropic effects of folate supplementation. Nutr J. 2004 ; 3: 4.
2. Groen V., Moser R. Synthesis of optically pure diastereoisomers of reduced folates. Pteridines. 1999 ; 10: 95-100.
3. Prinz-Langenohl R., Fohr I., Tobolski O., Finglas P., Pietrzik K. Bioavailability of 6S-5-methyltetrahydrofolate relative to folic acid. Bioavailability. 2001 ; Interlaken, Switzerland.
4. Wu D., Pardridge WM Blood-brain barrier transport of reduced folic acid. Pharm Res. 1999 ; 16: 415-419.
5. Troen AM, Mitchell B., Sorensen B., et al. Unmetabolized folic acid in plasma is associated with reduced natural killer cell cytotoxicity among postmenopausal women. J Nutr. 2006 ; 136: 189-194.
6. Hasselwander O., Hönlein W., Schweillert L., Krömer K. 5-Methyltetrahydrofolate-the active form of folic acid. Functional Foods 2000, Conference Proceedings ; pp 48-59.
7. Kelly P., McPartlin I., Goggins M., Weir DG, Scott IM Unmetabolized folic acid in serum: acute studies in subjects consuming fortified food and supplements. Am J Clin Nutr. 1997 ; 65: 1790-1795.
8. Scott JM, Weir DG The methyl folate trap. A physiological response in man to prevent methyl group deficiency in kwashiorkor (methionine deficiency) and an explanation for folic acid-induced exacerbation of subacute combined degeneration in pernicious anemia. Lancet. 1981 ; 2: 337-340.
9. Weir DG, Scott JM Brain function in the elderly: role of vitamin B12 and folate. Br Med Bull. 1999 ; 55: 669-682.
10. Ulvik A., Evensen ET, Lien EA, et al. Smoking, folate, and methylenetetrahydrofolate reductase status as interactive determinants of adenomatous and hyperplastic polyps of colorectum. Am J Med Genet. 2001 ; 101: 246-254.
11. Reynolds EH Folic acid, ageing, depression, and dementia. BMJ. 2002 ; 324: 1512-1515.
12. Arinami T., Yamada N., Yamakawa-Kobayashi K., et al. Methylenetetrahydrofolate reductase variant and schizophrenia/depression. Am J Med Genet. 1997 ; 74: 526-528.
13. Kelly CB, McDonnell AP, Johnston TG, et al. The MTHFR C677T polymorphism is associated with depressive episodes in patients from Northern Ireland. J Psychopharmacol. 2004 ; 18: 567-571.
14. Lewis SJ, Lawlor DA, Smith DG, et al. The thermolabile variant of MTHFR is associated with depression in the British Women's Heart and Health Study and a meta-analysis. Mol Psychiatry. 2006 ; 11: 352-360.
15. Bezold G., Lange M., Peter RU Homozygous methylenetetrahydrofolate reductase C677T mutation and male infertility. NEJM. 2001 ; 344: 1172-1173.
16. Frosst P., Blom HJ, Milos R., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylene-tetrahydrofolate reductase. Nat Genet. 1995 ; 10: 111-113.
17. de Bree A., Verschuren WMM, Bjørke-Monsen A-L., et al. Effect of the methylenetetrahydrofolate reductase 677C>T mutation on the relations among folate intake and plasma folate and homocysteine concentrations in a general population sample. Am J Clin Nutr. 2003 ; 77: 687-693.
18. Bottiglieri T. Homocysteine and folate metabolism in depression. Progr NeuroPsychopharmacol Bioll Psychiatry. 2005 ; 29: 1103-1112.
19. Papakostas GI, Petersen T., Mischoulon D., et al. Serum folate, vitamin B12, and homocysteine in major depressive disorder, part 1: predictors of clinical response in fluoxetine-resistant depression. J Clin Psychiatry. 2004 ; 65: 1090-1095.
20. Lindenbaum J., Whitehead N., Reyner F. Oral contraceptive hormones, folate metabolism, and the cervical epithelium. Am J Clin Nutr. 1975 ; 28: 346-353.
21. Abou-Saleh MT, Coppen A. The biology of folate in depression: implications for nutritional hypotheses of the psychoses. J Psychiatr Res. 1986 ; 20: 91-101.
22. Abou-Saleh MT, Coppen A. Serum and red blood cell folate in depression. Acta Psychiatr Scand. 1989 ; 80: 78-82.
23. Maurizio F., Thase ME Pharmacologic Management of Treatment-Refractory Depression. Medscape. June 28, 2007. Accessed on May 29, 2008 at http://www.medscape.com/viewprogram/7333.
24. Herbert V. Experimental nutritional folate deficiency in man. Trans Assoc Am Physicians. 1962 ; 75: 307-320.
25. Alpert JE, Fava M. Nutrition and depression: the role of folate. Nutr Rev. 1997 ; 55: 145-149.
26. Reynolds EH, Preece JM, Bailey J., et al. Folate deficiency in depressive illness. Br Psychiatry. 1970 ; 117: 287-292.
27. Fava M., Borus JS, Alpert JE, Nierenberg AA, Rosenbaum JF, Bottiglieri T. Folate, vitamin B12, and homocysteine in major depressive disorder. Am J Psychiatry. 1997 ; 154: 426-428.
28. Coppen A., Bolander-Gouaille C. Treatment of depression: time to consider folic acid and vitamin B12. J Psychopharmacol. 2005 ; 19: 59-65.
29. Bottiglieri T., Hyland K., Laundy M., et al. Folate deficiency, biopterin and monoamine metabolism in depression. Psychol Med. 1992 ; 22: 871-876.
30. Morris MS, Fava M., Jacques PF, Selhub J., Rosenberg IH Depression and folate status in the US population. Psychother Psychosom. 2003 ; 72: 80-87.
31. Bjelland I., Tell GS, Vollset SE, Refsum H., Ueland PM Folate, vitamin B12, homocysteine, and the MTHFR 677C-:T polymorphism in anxiety and depression: the Hordaland homocysteine study. Arch Gen Psychiatry. 2003 ; 60: 618-626.
32. Tolmunen T., Voutilainen S., Hintikka J., et al. Dietary folate and depressive symptoms are associated in middle-aged Finnish men. J Nutr. 2003 ; 133: 3233-3236.
33. Mann JJ Drug therapy: the medical management of depression. NEJM. 2005 ; 353: 1819-1834.
34. Farrar G., Blair JA Pterins in depression a modified monoamine hypothesis. In: Copeland JR, Aboo-Saleh MT, Blazer DG, eds. Principles and Practice of Geriatric Psychiatry. NJ: John Wiley and Sons ; 1994: 543-546.
35. Paul RTP, McDonnell AP, Kelly CB Folic acid: neuro-chemistry, metabolism and relationship to depression. Human Psychopharmacol. 2004 ; 19: 477-488.
36. Stahl SM Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressant-augmenting agent. CNS Spectr. 2007 ; 12: 739-744.
37. Bottiglieri T., Laundy M., Crellin R., Toone BK, Carney MW, Reynolds EH Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry. 2000 ; 69: 228-232.
38. Ponzone A., Spada M., Ferraris S., Dianzani I., deSanctis L. Dihydropteridine reductase deficiency in man: from biology to treatment. Med Res Rev. 2004 ; 24: 127-150.
39. Goldstein DS, Hahn S. -H, Holmes C., et al. Monoaminergic effects of folinic acid, L-dopa and 5-hydroxytryptophan in dihydropteridine reductase deficiency. J Neurochem. 1995 ; 64: 2810-2813.
40. Lucock MD, Green M., Levene MI Methylfolate modulates potassium evoked neuro-secretion: evidence for a role at the pteridine cofactor level of tyrosine 3-hydroxylase. Neurochem Res. 1995 ; 20: 727-736.
41. Niederwieser A. Inborn errors of pterin metabolism. In: Botez MI, Reynolds EH, eds. Folic Acid in Neurology, Psychiatry and Internal Medicine. New York, NY: Raven Press ; 1979: 349-384.
42. Hamon CGB, Blair JA, Barford PA The effect of tetrahydrofolate on tetrahydrobipterin metabolism. J Ment Defic Res. 1986 ; 30: 179-183.
43. Matthews RG, Kaufman S. Characterization of the dihydropterin reductase activity of pig liver methylenetetrahydrofolate reductase. J Biol Chem. 1980 ; 255: 6014-6017.
44. Vanoni MA, Ballou DP, Matthews RG Methylenetetrahydrofolate reductase. J Biol Chem. 1983 ; 258: 11510-11514.
45. Turner AJ The relationship between brain folate and monoamine metabolism. In: Botez MI, Reynolds EH, eds. Folic Acid in Neurology, Psychiatry and Internal Medicine. New York, NY: Raven Press; 1979: 165-177.
46. Cantoni GL S-Anenysylmethionine: a new intermediate formed enzymatically from 1-methionine and adenosine triphosphate. Biol Chem. 1953 ; 204: 403-416.
47. Hendler SS, Rorvik D, eds. PDR for Nutritional Supplements, 1 st ed. Montvale NJ: Thomson PDR ; 2001: 410-414.
48. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with Citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. AM J Psychiatry. 2006 ; 163: 28-40.
49. Fava M., Davidson KG Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996 ; 119: 176.
50. Carney MW, Chary TK, Laundy M., et al. Red cell folate concentrations in psychiatric patients. J Affect Disord. 1990 ; 19: 207-213.
51. Lerner V. Vitamin B12 and folate serum levels in newly admitted psychiatric patients. Clin Nutr. 2006 ; 25: 60-67.
52. Papakostas GI, Petersen T., Lebowitz BD, et al. The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. Int J Neuropsychopharmacol. 2005 ; 8: 1-6.
53. Alpert M., Silva RR, Pouget ER Prediction of treatment response in geriatric depression from baseline folate level: interaction with an SSRI or a tricyclic antidepressant. J Clin Psychopharm. 2003 ; 23: 309-313.
54. Papakostas GI Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (part II). Psychiatry Res. 2005 ; 140: 291-299.
55. Levitt A., Joffe RT Folate, B12, and life course of depressive illness. Biol Psychiatry. 1989 ; 25: 867-872.
56. Wesson VA, Levitt AJ, Joffe RT Change in folate status with antidepressant treatment. Psychiatry Res. 1994 ; 53: 313-322.
57. Papakostas GI, Iosifescu D., Renshaw P., et al. Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (part II). Psychiatry Res: Neuroimaging. 2005 ; 140: 301-307.
58. Fava M., Rush J. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom. 2006 ; 75: 139-153.
59. Papakostas GI, Petersen T., Mischoulon D., et al. Serum folate, vitamin B12, and homocysteine in major depressive disorder, part 2: predictors of relapse during the continuation phase of pharmacotherapy. J Clin Psychiatry. 2004 ; 65: 1096-1098.
60. Alpert JE Nutrition and depression: focus on folate. Nutrition. 2000 ; 16: 544-546.
61. Gray GE Nutrition and dementia. J Am Diet Assoc. 1989 ; 89: 1795-1802.
62. Guaraldi GP, Fava M., Mazzi F., La Greca P. An open trial of methyltetrahydrofolate in elderly depressed patients. Ann Clin Psychiatry. 1993 ; 5: 101-105.
63. Di Palma C., Urani R., Agricola R., Giorgetti V., Dalla Verde G. Is methylfolate effective in relieving major depression in chronic alcoholics? A hypothesis of treatment. Curr Ther Res. 1994 ; 55: 559-568.
64. Taylor MJ, Carney S., Goodwin GM, Geddes J. Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials. J Psychopharm. 2004 ; 18: 251-256.
65. Coppen A., Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomized, placebo controlled trial. J Affect Disorders. 2000 ; 60: 121-130.
66. Coppen A., Chaudhry S., Swade C. Folic acid enhances lithium prophylaxis. J Affect Disord. 1986 ; 10: 9-13.
67. Alpert JE, Mischoulon D., Rubenstein GE, Bottonari K., Nierenberg AA, Fava M. Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. Ann Clin Psychiatry. 2002 ; 14: 33-38.
68. Opinion of the scientific panel on food additives, flavourings, processing aids and materials in contact with food on a request from the commission related to calcium L-methylfolate. EFSA J. 2004 ; 135: 1-20. Available at: http://www.food.gov.uk/multimedia/pdfs/acnfp8406mthf. Accessed September 3, 2007.
69. Gilbody S., Lewis S., Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. Am J Epidemiol. 2007 ; 165: 1-13.